Table 3 Prognostic factors for BCSS and OS by multivariable proportional hazards regression.

From: The impact of axillary lymph node dissection on the prognosis of breast cancer patients undergoing up-front mastectomy with Sentinel lymph node micrometastases

Characteristics

BCSS

OS

HRs (95% CI)

P value

HRs (95% CI)

P value

Age (years)

< 49

1.00

 

1.00

 

50–64

1.24(0.90, 1.73)

0.2

1.42(1.09, 1.85)

0.01

> 65

1.82(1.29, 2.59)

< 0.001

3.19(2.47, 4.13)

< 0.001

Marital status

Single

1.00

 

1.00

 

Married

0.67(0.46, 0.98)

0.037

0.54(0.42, 0.70)

< 0.001

DSW

1.11(0.74, 1.67)

0.6

1.09(0.83, 1.41)

0.5

Income

<$75,000

1.00

 

1.00

 

>$75,000

0.92(0.70, 1.21)

0.6

0.82(0.68, 0.98)

0.031

Race

White

1.00

 

1.00

 

Black

1.29(0.88, 1.87)

0.2

1.35(1.06, 1.72)

0.016

Others

0.61(0.37, 1.01)

0.054

0.59(0.41, 0.84)

0.003

Primary Site

Central portion

1.00

 

1.00

 

Upper outer

0.72(0.54, 0.96)

0.023

0.84(0.70, 0.98)

0.045

Other sites

0.72(0.44, 1.20)

0.2

1.18(0.90, 1.56)

0.2

Histology

IDC

1.00

 

1.00

 

ILC

0.79(0.49, 1.26)

0.3

0.96(0.72, 1.27)

0.8

Others

0.55(0.36, 0.84)

0.006

0.86(0.68, 1.09)

0.2

Grade

I

1.00

 

1.00

 

II

1.68(1.05, 2.69)

0.031

1.16(0.91, 1.47)

0.2

III

2.96(1.75, 5.00)

< 0.001

1.69(1.27, 2.26)

< 0.001

T stage

T1

1.00

 

1.00

 

T2

1.47(1.14, 1.90)

0.003

1.32(1.11, 1.56)

0.002

Subtype

HR+/HER2-

1.00

 

1.00

 

HR+/HER2+

0.63(0.38, 1.03)

0.064

1.06(0.77, 1.44)

0.7

HR-/HER2+

0.81(0.43, 1.52)

0.5

0.95(0.58, 1.57)

0.9

HR-/HER2-

2.06(1.39, 3.06)

< 0.001

1.8(1.28, 2.53)

< 0.001

Number of metastatic sentinel-nodes

1

1.00

 

1.00

 

2 or 3

1.49(1.05, 2.11)

0.025

1.34(1.05, 1.72)

0.018

Chemotherapy

No

1.00

 

1.00

 

Yes

1.24(0.87, 1.76)

0.2

0.73(0.59, 0.90)

0.004

Surgery

Non-ALND

1.00

 

1.00

 

ALND

0.86(0.61, 1.02)

0.069

0.86(0.73, 1.02)

0.086

  1. ALND axillary lymph node dissection, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, HR hormone receptor, HER2 human epidermal growth factor 2, DSW divorced widowed separated, BCSS breast cancer-specific survival, OS overall survival, HRs hazard ratios, CI confidence interval.